Compare Amylx Pharmaceuticals Inc (AMLX) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while YieldMax MSTR Option Income Strategy ETF trades at $12.63. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | MSTY | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $18.70 | $114.30 |
52-Week Low | $7.64 | $11.55 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MSTY trades at $12.83, up 0.79% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF maintains a high distribution schedule, paying weekly dividends, though recent news highlights concerns over uncapped losses and NAV erosion. Support is clustered around $12-$13, with resistance just above the current price.
Outlook remains cautious due to structural risks from the covered-call strategy capping upside. High yield appeals to income seekers, but total return depends on preserving capital. Key risks include Strategy stock volatility and return-of-capital distributions undermining long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
